Nastech Announces Multi-Compound Agreement with Novo Nordisk
News Mar 20, 2006
Nastech Pharmaceutical Company Inc. has announced that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.
"Nastech is honored to be working with Novo Nordisk, a world-leader in therapies for metabolic disease," said Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.
"Novo Nordisk is known for its ethical standards and has participated in many innovative advances in medical practice."
Helping people with addictions has become a research passion for Purdue University researchers who is leading a team to make drug discoveries to support millions around the world dealing with alcohol use disorders, chronic pain and mood disorders. The team's recent discovery provides a new avenue for the development of medications that provide therapeutic relief for a patient without causing unwanted side effects.READ MORE
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019